Please login to the form below

Not currently logged in
Email:
Password:

Galapagos in osteoporosis tie up with Lilly

Galapagos enters into a global collaboration agreement with US-based Eli Lilly to develop potential new medicines for the treatment of osteoporosis

Belgian-headquartered biotech Galapagos has entered into a global collaboration agreement with US-based Eli Lilly to develop potential new medicines for the treatment of osteoporosis.

Galapagos uses its SilenceSelect and FLeXSelect platforms to discover and validate novel osteoporosis targets.

The agreement provides Lilly access to 12 of these proprietary osteoporosis targets and drug discovery programmes to discover candidate drugs. Galapagos will be responsible for the development of drug candidates potentially through to phase IIa clinical proof-of-concept.

Per the agreement, Lilly will have the exclusive option to further develop and commercialise clinical candidates globally. Galapagos will have the right to further develop and commercialise compounds for which Lilly does not exercise its option.

Galapagos will receive a EUR 3m upfront payment from Lilly.

If the company achieves certain milestones, Galapagos will be eligible for each target programme to receive up to EUR 88m in discovery, development and regulatory milestones. Should commercialisation occur, Galapagos could receive up to EUR 130m of one-time sales milestones and up to double-digit royalties on global sales of such products.

In the collaboration with Galapagos, Lilly says will leverage its own internal expertise with the osteoporosis treatments Evista (raloxifene), Forteo (teriparatide) and arzoxifene.

In October 2007, Galapagos has teamed up with Johnson & Johnson (J&J) in an arthritis research programme. The two-part deal was made up of an alliance and an internal R&D programme at Galapagos to develop rheumatoid arthritis (RA) treatments. The company said it could receive a total of EUR 1bn (USD 1.4bn) for approximately five or six first-in-class drugs.

19th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics